JP2014520767A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520767A5
JP2014520767A5 JP2014517492A JP2014517492A JP2014520767A5 JP 2014520767 A5 JP2014520767 A5 JP 2014520767A5 JP 2014517492 A JP2014517492 A JP 2014517492A JP 2014517492 A JP2014517492 A JP 2014517492A JP 2014520767 A5 JP2014520767 A5 JP 2014520767A5
Authority
JP
Japan
Prior art keywords
group
atoms
hal
cyc
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520767A (ja
JP6116554B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/002469 external-priority patent/WO2013004332A1/en
Publication of JP2014520767A publication Critical patent/JP2014520767A/ja
Publication of JP2014520767A5 publication Critical patent/JP2014520767A5/ja
Application granted granted Critical
Publication of JP6116554B2 publication Critical patent/JP6116554B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517492A 2011-07-07 2012-06-11 がんの処置のための置換されたアザ複素環 Expired - Fee Related JP6116554B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505376P 2011-07-07 2011-07-07
US61/505,376 2011-07-07
PCT/EP2012/002469 WO2013004332A1 (en) 2011-07-07 2012-06-11 Substituted azaheterocycles for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2014520767A JP2014520767A (ja) 2014-08-25
JP2014520767A5 true JP2014520767A5 (enExample) 2015-07-30
JP6116554B2 JP6116554B2 (ja) 2017-04-19

Family

ID=46354143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517492A Expired - Fee Related JP6116554B2 (ja) 2011-07-07 2012-06-11 がんの処置のための置換されたアザ複素環

Country Status (9)

Country Link
US (1) US9199962B2 (enExample)
EP (1) EP2729459B1 (enExample)
JP (1) JP6116554B2 (enExample)
CN (1) CN103649074B (enExample)
AU (1) AU2012280725B2 (enExample)
CA (1) CA2840883C (enExample)
ES (1) ES2698847T3 (enExample)
IL (1) IL230218A (enExample)
WO (1) WO2013004332A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
KR20150044952A (ko) * 2012-08-23 2015-04-27 에프. 호프만-라 로슈 아게 암의 치료를 위한 신규한 페닐-피리딘/피라진 아미드
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
PH12015501130B1 (en) * 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
EP2938610A2 (en) * 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
WO2014138460A1 (en) 2013-03-07 2014-09-12 Northwestern University 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
MX370588B (es) 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
KR101823488B1 (ko) 2013-10-14 2018-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
WO2016073623A2 (en) * 2014-11-04 2016-05-12 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
EP3630291B9 (en) * 2017-05-26 2024-05-29 Cancer Research Technology Limited Benzimidazolone derived inhibitors of bcl6
IL296734B2 (en) 2018-04-13 2025-06-01 The Institute Of Cancer Res Royal Cancer Hospital Bcl6 inhibitors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス, インコーポレイテッド 膵臓癌を治療する方法
WO2020116296A1 (ja) 2018-12-07 2020-06-11 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法
JP7471407B2 (ja) 2020-05-19 2024-04-19 ユニマテック株式会社 含フッ素ピリミジン化合物および含フッ素ピリミジノン化合物
US12213973B2 (en) 2021-10-18 2025-02-04 Northwestern University Bacterial nitric oxide synthase inhibitors
US12522580B2 (en) 2021-11-12 2026-01-13 Unimatec Co., Ltd. Fluorine-containing pyrimidine compounds, harmful fungus control agent, and method for producing fluorine-containing pyrimidine compounds
IL316542A (en) * 2022-04-29 2024-12-01 Jiangsu Yahong Meditech Co Ltd Pyrimidine compound, method for its preparation, and pharmaceutical use thereof
TW202425982A (zh) * 2022-11-04 2024-07-01 大陸商深圳晶泰科技有限公司 泛素特異性蛋白酶1的抑制劑及其應用
WO2025007777A1 (zh) * 2023-07-05 2025-01-09 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0640599B1 (en) * 1993-08-26 1998-03-04 Ono Pharmaceutical Co., Ltd. 4-Aminopyrimidine derivatives
WO1996033972A1 (en) * 1995-04-28 1996-10-31 Glaxo Group Limited Methods for synthesizing diverse collections of pyridines, pyrimidines, 1,4-dihydro derivatives thereof, and piperidine derivatives
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
DK1330452T3 (da) * 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (en) 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
AU2003214110A1 (en) * 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7459460B2 (en) * 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
CA2531061A1 (en) * 2003-07-02 2005-01-13 Vertex Pharmaceuticals Incorporated Pyrimidines useful as modulators of voltage-gated ion channels
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
AU2005225471B2 (en) * 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
CN103087043A (zh) * 2007-03-16 2013-05-08 中国人民解放军军事医学科学院放射与辐射医学研究所 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂
KR20090129488A (ko) 2007-03-22 2009-12-16 버텍스 파마슈티칼스 인코포레이티드 야누스 키나아제의 억제제로서 유용한 n-헤테로사이클릭 화합물
US20090048282A1 (en) 2007-08-14 2009-02-19 Wyeth Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
EP2193370A2 (en) 2007-09-24 2010-06-09 Fibrex Medical Research & Development GmbH Methods of screening for compounds having anti-inflammatory activity
JP2010126496A (ja) * 2008-11-28 2010-06-10 Mitsubishi Tanabe Pharma Corp 複素環化合物
JP5263304B2 (ja) * 2009-02-06 2013-08-14 日本新薬株式会社 アミノピラジン誘導体及び医薬
WO2010126922A1 (en) 2009-04-30 2010-11-04 Glaxosmithkline Llc Benzimidazolecarboxamides as inhibitors of fak
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2013066839A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods

Similar Documents

Publication Publication Date Title
JP2012506389A5 (enExample)
JP2013501047A5 (enExample)
JP2016503797A5 (enExample)
AR118341A2 (es) Mezclas fungicidas ternarias
JP2015536947A5 (enExample)
JP2012532899A5 (enExample)
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
JP2014508753A5 (enExample)
JP2012092103A5 (enExample)
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
JP2015522650A5 (enExample)
JP2014508811A5 (enExample)
JP2018533593A5 (enExample)
JP2012516871A5 (enExample)
RU2014103587A (ru) Производные циклических аминов в качестве антагонистов рецептора ер4
JP2015535847A5 (enExample)
HRP20161103T1 (hr) Kemijski spojevi
JP2017501237A5 (enExample)
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
JP2012508252A5 (enExample)
JP2011219498A5 (enExample)
JP2014511891A5 (enExample)
JP2013532668A5 (enExample)